Last $3.30 USD
Change Today -0.02 / -0.60%
Volume 209.3K
ZIOP On Other Exchanges
As of 2:13 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

ziopharm oncology inc (ZIOP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/14 - $5.58
52 Week Low
08/20/13 - $2.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZIOPHARM ONCOLOGY INC (ZIOP)

ziopharm oncology inc (ZIOP) Related Bloomberg News

View More Bloomberg News

ziopharm oncology inc (ZIOP) Related Businessweek News

No Related Businessweek News Found

ziopharm oncology inc (ZIOP) Details

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the discovery and development of cancer therapies that address unmet medical needs through synthetic biology. The company is employing novel gene expression and control technology to deliver DNA for the treatment of cancer. Its technology platform employs Intrexon Corporation’s RheoSwitch Therapeutic System platform to turn on and off, and modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is being evaluated in Phase II clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The company is also developing novel small molecules as potential cancer therapeutics. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

43 Employees
Last Reported Date: 03/3/14

ziopharm oncology inc (ZIOP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $600.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $230.3K
President of Research & Development and Chief...
Total Annual Compensation: $121.9K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $411.3K
Total Annual Compensation: $206.3K
Compensation as of Fiscal Year 2013.

ziopharm oncology inc (ZIOP) Key Developments

ZIOPHARM Oncology, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 10:00 AM

ZIOPHARM Oncology, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 10:00 AM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Francois Lebel, Senior Vice President of Clinical Development and Medical Operations, Jonathan J. Lewis, Chief Executive Officer and Director.

ZIOPHARM Oncology, Inc. Presents at Boston CEO Conference, Jun-04-2014 03:00 PM

ZIOPHARM Oncology, Inc. Presents at Boston CEO Conference, Jun-04-2014 03:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Jonathan J. Lewis, Chief Executive Officer and Director.

ZIOPHARM Oncology, Inc. Announces Oral Presentation Ad-RTS-IL-12 Results Correlated with Reducing Cancer Stem Cells in the Brain

ZIOPHARM Oncology, Inc. announced results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other preclinical and clinical settings. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response. The presentation, titled 'Intratumoral Regulated Expression of IL-12 as a Gene Therapy Approach to Immunotherapy,' was presented in an oral session at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 21-24 in Washington, DC. Results from human and laboratory studies of Ad-RTS-IL-12 demonstrate that precise control of IL-12 gene expression levels can be achieved using Intrexon Corporation's RheoSwitch Therapeutic System(R) (RTS(R)). Rapid, tight modulation of in vivo expression of IL-12 using the activator ligand veledimex was demonstrated across these studies. When IL-12 expression is 'switched on' it rapidly leads to expression and an immune response. This immune response is characterized by an increase in tumor infiltrating lymphocytes with system wide immune activation. This modulated immune response has resulted in anti-tumor effects in both injected and systemic non-injected legions in Phase 1 and Phase 2 studies of Ad-RTS-IL-12 in subjects with melanoma and breast cancer. The data presented further demonstrate that Ad-RTS-IL-12 has potent anti-cancer effects in a glioma model, showing both a reduction in tumor mass and prolonged survival when compared to existing treatment standards. The data also show a significant reduction in brain cancer stem cells, as measured by dramatically reduced nestin levels. Brain cancer stem cells are thought to play a critical role in recurrence and metastasis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZIOP:US $3.30 USD -0.02

ZIOP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $2.90 USD 0.00
Argos Therapeutics Inc $6.51 USD +0.01
Genocea Biosciences Inc $17.67 USD -0.36
GenVec Inc $2.20 USD -0.01
Progenics Pharmaceuticals Inc $5.03 USD +0.035
View Industry Companies

Industry Analysis


Industry Average

Valuation ZIOP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 416.0x
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 342.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIOPHARM ONCOLOGY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at